The president-elect has vowed to strengthen the Affordable Care Act, which gave millions of Americans health insurance. But many insured people still struggle to pay for health care, research finds. More
This economic evaluation study estimates the number of patients with cancer who are eligible for the newly approved drug-indication pairs and projects potential spending and use of the approvals in the United States. More
A surprise charge that can take advantage of vulnerable people and possibly violate consumer protection laws. More
The idea behind the new regulations on insurers is to empower patients to become better consumers of health care, thereby helping to drive down costs. More
Gilead said it spent $1 billion to develop remdesivir. The NIH invested as much as $6.5 billion in it between 2000 and 2019. More
Federal law eliminates consumer cost sharing for multiple methods of colorectal cancer screening, including colonoscopy when done by an in-network provider. However, some patients having screening incur considerable out-of-pocket costs because out-of-network bills are not included in federal mandates. More
In a letter to the drug maker, the state treasurers warn that prices “disconnected from market forces will ultimately backfire." More
The CARES Act lets out-of-network providers set their own prices for COVID-19 diagnostic and antibody tests. A new study finds that has resulted in a wide range of charges. More
Studies show that at least half of ground ambulance rides across the nation leave patients with “surprise” medical bills. And a $300-a-mile ride is not unusual. More
This NPR, Harvard T.H. Chan School of Public Health, and RWJF polling series examines the most serious health and financial problems facing households across America prior to the expiration of federal coronavirus support programs. More